Editas Medicine (EDIT) Cash & Equivalents (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Cash & Equivalents data on file, last reported at $146.6 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $146.6 million, up 11.48% year-over-year; the trailing twelve-month figure through Dec 2025 was $146.6 million (up 11.48% YoY), and the FY2025 annual result was $146.6 million, up 11.48% from the prior year.
• Cash & Equivalents fell to $146.6 million in Q4 2025 per EDIT's latest filing, from $165.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $354.9 million in Q1 2021 and troughed at $64.4 million in Q2 2024.
• A 5-year average of $169.8 million and a median of $144.1 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 70.82% in 2024, then jumped 114.99% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $203.5 million in 2021, then sank by 30.46% to $141.5 million in 2022, then retreated by 12.63% to $123.7 million in 2023, then increased by 6.38% to $131.5 million in 2024, then increased by 11.48% to $146.6 million in 2025.
• Business Quant data shows EDIT's Cash & Equivalents at $146.6 million in Q4 2025, $165.6 million in Q3 2025, and $138.5 million in Q2 2025.